Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06547385
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-08-01
Brief Title:
Study of ONO-4578 and XELOXFOLFOX Plus Bevacizumab in Colorectal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
ONO-4578 Phase I Study An Open-label Uncontrolled Study of First-line Combination Therapy of ONO-4578 and ONO-4538 With Standard Therapy XELOX Plus Bevacizumab or FOLFOX Plus Bevacizumab in Patients With Unresectable Advanced or Recurrent Colorectal Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX bevacizumab as first-line therapy in patients with unresectable advanced or recurrent colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None